皮肤黑色素瘤新辅助治疗的研究进展  

Advances in Neoadjuvant Therapy for Cutaneous Melanoma

作　　者：康东林 赵莲君 任宇 苏欣宇 邹征云 KANG Donglin;ZHAO Lianjun;REN Yu;SU Xinyu;ZOU Zhengyun(Cancer Center,Nanjing Drum Tower Hospital/Clinical College of Nanjing Medical University,Nanjing 210008,China;The Comprehensive Cancer Center of Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School,Nanjing 210008,China;Clinical Cancer Institute of Nanjing University,Nanjing 210008,China)

机构地区：[1]南京医科大学附属鼓楼临床医学院肿瘤中心,江苏南京210008 [2]南京大学医学院附属鼓楼医院综合肿瘤中心,江苏南京210008 [3]南京大学临床肿瘤学研究所,江苏南京210008

出　　处：《中国肿瘤》2024年第12期1033-1041,共9页China Cancer

基　　金：国家自然科学基金(82073365)。

摘　　要：恶性黑色素瘤是一种恶性程度高、预后差的皮肤恶性肿瘤。然而,免疫疗法和靶向疗法的出现显著改善了晚期可切除黑色素瘤的预后,这也使得黑素色瘤患者的新辅助治疗成为可能。目前,已有多项相关新辅助治疗临床研究取得了一定成果。全文主要对皮肤黑色素瘤新辅助治疗的选择、后续手术方式、预后指标以及基线生物标志物等问题进行梳理,希望为皮肤黑色素瘤的治疗提供更多思路。Cutaneous melanoma is a malignant skin cancer with a poor prognosis.However,recent advances in immune checkpoint blockade and targeted therapy have significantly improved outcomes in advanced-stage resectable melanoma,which have made neoadjuvant therapy a viable option for melanoma patients.Currently,several relevant clinical trials on neoadjuvant therapy have achieved significant results.This paper reviews the recent advances in neoadjuvant therapy for cutaneous melanoma,focusing on the selection of neoadjuvant therapy,subsequent surgical considerations after neoadjuvant therapy,prognostic indicators,and baseline biomarkers.

关 键 词：皮肤黑色素瘤 新辅助治疗 免疫治疗 靶向治疗 辅助治疗 

分 类 号：R739.55[医药卫生—肿瘤]